Showing results (331-340 of 354) with videos related to

Sort By:
Pageof 36
Journal of Virology|October 10, 2008
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremiaGeorgia D Tomaras, Nicole L Yates, Pinghuang Liu, et al.
PLOS Global Public Health|September 20, 2024
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trialVimla Naicker, Fatima Laher, Linda-Gail Bekker, et al.
Plos Medicine|May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trialsZoe Moodie, Stephen R Walsh, Fatima Laher, et al.
The Journal of Clinical Investigation|October 8, 2019
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 riskScott D Neidich, Youyi Fong, Shuying S Li, et al.
Journal of Virology|November 24, 2012
Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletionS Munir Alam, Hua-Xin Liao, Georgia D Tomaras, et al.
Scientific Reports|December 29, 2019
Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vectorM Giel-Moloney, M Esteban, B H Oakes, et al.
Science Translational Medicine|March 21, 2014
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccinationNicole L Yates, Hua-Xin Liao, Youyi Fong, et al.
Nature Medicine|September 28, 2018
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individualsYotam Bar-On, Henning Gruell, Till Schoofs, et al.
Ebiomedicine|June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling studyYunda Huang, Lily Zhang, Huub Gelderblom, et al.
Nature Medicine|May 13, 2022
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trialBoris Julg, Kathryn E Stephenson, Kshitij Wagh, et al.
Pageof 36